Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial

ConclusionsVICTORIA comprises a broadly generalizable high ‐risk population of three unique clinical strata of worsening chronic HFrEF despite very good HF therapy. VICTORIA will establish the role of vericiguat, a soluble guanylate cyclase stimulator, in HFrEF.

Source: European Journal of Heart Failure - December 8, 2019 Category: Cardiology Authors: Burkert Pieske, Mahesh J. Patel, Cynthia M. Westerhout, Kevin J. Anstrom, Javed Butler, Justin Ezekowitz, Adrian F. Hernandez, Joerg Koglin, Carolyn S.P. Lam, Piotr Ponikowski, Lothar Roessig, Adriaan A. Voors, Christopher M. O'Connor, Paul W Tags: Research Article Source Type: research